GlassScriptPhysician profile
Diana Katherine Ramirez
NPI 1215500087
$2,036.62
in general payments reported to CMS, 2019-2025
14 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $43.67 · 2024: $968 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.36 |
| Education | $248.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $379.33 | 2024-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $343.17 | 2024-2025 | |
| Abbvie INC. | $305.88 | 2024-2025 | |
| Ucb, INC. | $233.23 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $194.44 | 2024-2025 | Ebglyss, Taltz, Zepbound |
| Janssen Biotech, INC. | $187.72 | 2024-2025 | Tremfya |
| Shionogi INC | $99.28 | 2023-2024 | Fetroja |
| Galderma Laboratories, L.P. | $75.77 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $65.39 | 2025 | Zoryve |
| Urgo Medical North America, LLC | $50.31 | 2024 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Merck Sharp & Dohme LLC | $46.79 | 2023-2024 | Recarbrio, Zerbaxa, Dificid |
| Novartis Pharmaceuticals Corporation | $18.64 | 2025 | |
| Biofrontera INC. | $18.38 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $18.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.